Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1-Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory Board
Updated STARt-001 results will highlight invikafusp alfa's single-agent activity in PD-1–resistant tumors using a biomarker-enrichment strategy Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck, who led the initial development of pembrolizumab (KEYTRUDA®)...
Updated STARt-001 results will highlight invikafusp alfa's single-agent activity in PD-1–resistant tumors using a biomarker-enrichment strategy Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck, who led the initial development of pembrolizumab (KEYTRUDA®)...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.